As filed with the Securities and Exchange Commission on May 15, 2023

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OF 1933

Terns Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

Delaware

 

98-1448275

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification Number)

 

 

1065 East Hillsdale Blvd., Suite 100
Foster City, California

 

 

94404

(Address of Principal Executive Offices)

 

(Zip Code)

2021 Incentive Award Plan

2021 Employee Stock Purchase Plan

(Full Title of the Plan)

Senthil Sundaram

Chief Executive Officer

Terns Pharmaceuticals, Inc.

1065 East Hillsdale Blvd., Suite 100

Foster City, California 94404

(650) 525-5535

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

 

 

Brian A. Johnson

Wilmer Cutler Pickering Hale and Dorr LLP

7 World Trade Center

250 Greenwich Street

New York, New York 10007

Telephone: (212) 230-8800

 

Copies to:

 

Bryan Yoon, Esq.

Chief Operating Officer and General Counsel

Terns Pharmaceuticals, Inc.

1065 East Hillsdale Blvd., Suite 100

Foster City, California 94404

(650) 525-5535

 

 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☒

 

 

Emerging growth company

☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

Proposed sale to take place as soon after the effective date of the
registration statement as awards under the plans are exercised and/or vest.

 

 

 

 

 

EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 3,223,389 shares of the Registrant’s common stock issuable under the following employee benefit plans for which Registration Statements of the Registrant on Forms S-8 (File No. 333-253085 and 333-263340) are effective: (i) the 2021 Incentive Award Plan, as a result of the operation of an automatic annual increase provision therein, which added 2,686,158 shares of common stock, and (ii) the 2021 Employee Stock Purchase Plan, as a result of the operation of an automatic annual increase provision therein, which added 537,231 shares of common stock.

INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON
FORM S-8

Pursuant to Instruction E of Form S-8, the contents of (i) the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on February 12, 2021 (File No. 333-253085) and (ii) the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 7, 2022 (File No. 333-263340) are incorporated by reference herein.

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the SEC.

Item 8. Exhibits

 

 

Incorporated by Reference

Filed Herewith

Exhibit Number

Exhibit Description

Form

Date

Number

4.1

Amended and Restated Certificate of Incorporation.

8-K

2/9/2021

3.1

 

4.2

Amended and Restated Bylaws.

8-K

2/9/2021

3.2

 

4.3

Form of Common Stock Certificate.

S-1/A

2/1/2021

4.2

 

5.1

Opinion of Wilmer Cutler Pickering Hale and Dorr LLP.

 

 

 

X

23.1

Consent of Ernst & Young LLP, independent registered public accounting firm.

 

 

 

X

23.2

Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1).

 

 

 

X

24.1

Power of Attorney. Reference is made to the signature page to the Registration Statement.

 

 

 

X

99.1(a)#

2021 Incentive Award Plan.

S-8

2/12/2021

99.2(a)

 

99.1(b)#

Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan.

S-1/A

2/1/2021

10.5(b)

 

99.1(c)#

Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2021 Incentive Award Plan.

S-1/A

2/1/2021

10.5(c)

 

99.1(d)#

Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Incentive Award Plan.

S-1/A

2/1/2021

10.5(d)

 

99.2#

2021 Employee Stock Purchase Plan.

S-8

2/12/2021

99.3

 

107

Filing Fee Table

 

 

 

X

 

# Indicates management contract or compensatory plan.

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foster City, State of California, on this 15th day of May, 2023.

 

Terns Pharmaceuticals, Inc

By:

/s/ Senthil Sundaram

Senthil Sundaram

Chief Executive Officer

 

 

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Senthil Sundaram, Mark Vignola, Ph.D. and Bryan Yoon, Esq., and each of them, with full power of substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

Signature

Title

Date

/s/ Senthil Sundaram

Chief Executive Officer and Director

(Principal Executive Officer)

May 15, 2023

Senthil Sundaram

 

/s/ Mark Vignola

Chief Financial Officer

(Principal Financial and Accounting Officer)

May 15, 2023

Mark Vignola, Ph.D.

s/ David Fellows

Chairman of the Board of Directors

May 15, 2023

David Fellows

/s/ Carl Gordon

Director

May 15, 2023

Carl Gordon, Ph.D., C.F.A.

/s/ Jeffrey Kindler

Director

May 15, 2023

Jeffrey Kindler, Esq.

/s/ Hongbo Lu

Director

May 15, 2023

Hongbo Lu, Ph.D.

/s/ Jill Quigley

Director

May 15, 2023

Jill Quigley, Esq.

/s/ Ann Taylor

Director

May 15, 2023

Ann Taylor, M.D.

/s/ Radhika Tripuraneni

Director

May 15, 2023

Radhika Tripuraneni, M.D.

 

 

 
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Terns Pharmaceuticals Charts.
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Terns Pharmaceuticals Charts.